Reata Pharmaceuticals Stock Forecast, Price & News

Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions

Is Reata Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reata Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Reata Pharmaceuticals stock.
View analyst ratings for Reata Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Reata Pharmaceuticals?

Wall Street analysts have given Reata Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Reata Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Reata Pharmaceuticals' next earnings date?

Reata Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Reata Pharmaceuticals.

How were Reata Pharmaceuticals' earnings last quarter?

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) released its earnings results on Monday, August, 9th. The company reported ($2.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.13) by $0.13. The company earned $2.22 million during the quarter, compared to analysts' expectations of $1.32 million. Reata Pharmaceuticals had a negative trailing twelve-month return on equity of 84.38% and a negative net margin of 3,498.16%. The company's revenue was down 27.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($2.03) earnings per share.
View Reata Pharmaceuticals' earnings history.

How has Reata Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Reata Pharmaceuticals' stock was trading at $157.86 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RETA shares have decreased by 30.5% and is now trading at $109.77.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for RETA?

3 Wall Street analysts have issued 1-year target prices for Reata Pharmaceuticals' stock. Their forecasts range from $155.00 to $244.00. On average, they anticipate Reata Pharmaceuticals' stock price to reach $217.80 in the next year. This suggests a possible upside of 98.4% from the stock's current price.
View analysts' price targets for Reata Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Reata Pharmaceuticals' key executives?

Reata Pharmaceuticals' management team includes the following people:

• J. Warren Huff, Chairman, President & Chief Executive Officer
• Manmeet Singh Soni, Executive VP, Chief Operating & Financial Officer
• W. Christian Wigley, Chief Scientific Officer, SVP & Founding Scientist
• Colin J. Meyer, Chief Research & Development Officer, Executive VP
• Edmund Doherty, Vice President-Medical Affairs

What is Warren Huff's approval rating as Reata Pharmaceuticals' CEO?

10 employees have rated Reata Pharmaceuticals CEO Warren Huff on Glassdoor.com. Warren Huff has an approval rating of 92% among Reata Pharmaceuticals' employees. This puts Warren Huff in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Reata Pharmaceuticals' key competitors?

Some companies that are related to Reata Pharmaceuticals include Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Zai Lab (ZLAB), CureVac (CVAC), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Evotec (EVTCY) and Mirati Therapeutics (MRTX).
View all of RETA's competitors.

What other stocks do shareholders of Reata Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reata Pharmaceuticals investors own include Approach Resources (AREX), Precision Drilling (PDS), First Financial Bankshares (FFIN), Synlogic (SYBX), NVIDIA (NVDA), Basic Energy Services (BAS), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO) and Archrock (AROC).

When did Reata Pharmaceuticals IPO?

(RETA) raised $60 million in an initial public offering on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray served as the underwriters for the IPO.

What is Reata Pharmaceuticals' stock symbol?

Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."

Who are Reata Pharmaceuticals' major shareholders?

Reata Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Invesco Ltd. (7.72%), Vanguard Group Inc. (7.00%), BlackRock Inc. (5.89%), Franklin Resources Inc. (3.83%), Price T Rowe Associates Inc. MD (2.93%) and FMR LLC (2.07%). Company insiders that own Reata Pharmaceuticals stock include Colin John Meyer, Elaine Castellanos, James W Traweek Jr, James Warren Huff, Jason Douglas Wilson and Michael D Wortley.
View institutional ownership trends for Reata Pharmaceuticals.

Which major investors are selling Reata Pharmaceuticals stock?

RETA stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Susquehanna International Group LLP, Franklin Resources Inc., California Public Employees Retirement System, Man Group plc, Tolleson Wealth Management Inc., Bank of America Corp DE, and Millennium Management LLC. Company insiders that have sold Reata Pharmaceuticals company stock in the last year include Colin John Meyer, Elaine Castellanos, James Warren Huff, and Michael D Wortley.
View insider buying and selling activity for Reata Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Reata Pharmaceuticals stock?

RETA stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., FMR LLC, BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., and Corriente Advisors LLC.
View insider buying and selling activity for Reata Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Reata Pharmaceuticals?

Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Reata Pharmaceuticals' stock price today?

One share of RETA stock can currently be purchased for approximately $109.77.

How much money does Reata Pharmaceuticals make?

Reata Pharmaceuticals has a market capitalization of $3.99 billion and generates $9.02 million in revenue each year. The company earns $-247,750,000.00 in net income (profit) each year or ($7.35) on an earnings per share basis.

How many employees does Reata Pharmaceuticals have?

Reata Pharmaceuticals employs 267 workers across the globe.

What is Reata Pharmaceuticals' official website?

The official website for Reata Pharmaceuticals is www.reatapharma.com.

Where are Reata Pharmaceuticals' headquarters?

Reata Pharmaceuticals is headquartered at 5320 LEGACY DRIVE, PLANO TX, 75024.

How can I contact Reata Pharmaceuticals?

Reata Pharmaceuticals' mailing address is 5320 LEGACY DRIVE, PLANO TX, 75024. The company can be reached via phone at (972) 865-2219 or via email at [email protected].